Han Bio Pharmaceutical company Celltrion plans to invest nearly $500 million to expand the production capacity of its US factory.

South Korean biopharmaceutical company Celltrion disclosed on November 19th local time that in response to US tariffs and increasing demand, the company plans to invest up to 700 billion Korean won to expand the production capacity of its US factory.